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A B S T R A C T
Background: Human Papillomavirus (HPV) vaccination of girls was introduced in Germany in 2007.
However, data on the distribution of vaccine-relevant HPV types in the general population in Germany in
the prevaccine era are limited.
Methods: Serum samples collected during the German National Health Interview and Examination
Survey 1998 (GNHIES98), a nationally representative study including men and women aged 18–79 years,
were tested for antibodies to 19 mucosal and cutaneous HPV types. Multivariable regression models were
developed to identify associations between demographic and behavioral characteristics and HPV
seropositivity.
Results: Of the 6517 serum samples tested, almost a quarter was seropositive for at least one of the nine
HPV vaccine types with no clear age-pattern. HPV-6 and HPV-59 were the most common mucosal types,
while HPV-1 and HPV-4 were the most common cutaneous HPV types. Factors independently associated
with HPV-16 seroprevalence were seropositive to other sexually transmitted infections and lifetime
number of sex partners, as well as urbanity (only among females).
Conclusions: Prevalence of naturally acquired antibodies to HPV types which can be prevented by
vaccination is high in both sexes and all age groups. These data can serve as baseline estimates to evaluate
the population-level impact of the current vaccination strategy.
© 2019 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
nc-nd/4.0/).
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About 200 different mucosal and cutaneous Human Papilloma-
virus (HPV) types have been characterized (Van Doorslaer et al.,
2017), but only a small fraction is classified as oncogenic by the
International Agency for Research on Cancer (IARC) (International
Agency on Research on Cancer (IARC), 2012). The so-called high-
risk (HR) types are considered to be causative agents of various
types of precancerous lesions and cancer in women and men
(International Agency on Research on Cancer (IARC), 2012;
Schiffman et al., 2007). This group includes HPV types 16 and 18
as well as e.g., 31, 33, 35, 45, 52, and 58. External benign genital
warts are mainly caused by low risk (LR) types 6 and 11
(International Agency on Research on Cancer (IARC), 2012).
Cutaneous HPV types of different genera are common on healthyiety for Infectious Diseases. This is an open access article under the CC BY-NC-ND
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several skin lesions such as benign skin warts (de Villiers et al.,
2004; International Agency on Research on Cancer (IARC), 2012),
and some types have been discussed to be involved in skin
carcinogenesis (Hufbauer and Akgül, 2017).
HPV prevalence differs mainly by HPV type but also by
anatomical infection site and age (Iftner et al., 2010). Genital
mucosal HPV are common sexually transmitted pathogens,
but most HPV-infected persons develop no visible signs or
symptoms. The majority of genital HPV infections are cleared
within 12–24 months (Trottier and Franco, 2006), and persistent
HPV infections with particular  HR types are associated with an
increased risk of anogenital or oropharyngeal cancer (de Villiers
et al., 2004; International Agency on Research on Cancer (IARC),
2012; Schiffman et al., 2009). DNA testing has become the
reference standard for the detection of current HPV infections
(Abreu et al., 2012). However, it is not an appropriate method
to assess previous infections (Robbins et al., 2014). Testing for
HPV-specific antibodies provides information about past HPV
exposure (Robbins et al., 2014; Tiggelaar et al., 2012). Therefore,
HPV serology has been established as an important method for
population-based studies focusing on type-specific cumulative
lifetime exposure to HPV.
In Germany, HPV vaccination of girls has been introduced in
2007. Only limited data are available on the prevalence of HPV
HR and LR types in the adult population of Germany (Michael
et al., 2008). Previous studies were mainly performed in highly
selected populations and focused on DNA prevalence in young
women (Delere et al., 2014; Hauck et al., 2015; Iftner et al., 2010;
Petry et al., 2013; Remschmidt et al., 2013). Worldwide, only a
few population-based studies have focused on type-specific
seroprevalence in men and women (Liu et al., 2016; Markowitz
et al., 2009; Newall et al., 2008; Scherpenisse et al., 2012). The
aim of our study was to determine the seroprevalence and
associated risk factors of 19 HPV types in 18–79 year-old women
and men living in Germany during the prevaccine era, using
blood samples from a large countrywide population-based
survey.
Subjects, materials, and methods
Study population and design
HPV seroprevalence was assessed by using archived serum
samples from a cross-sectional population-based health survey.
The German National Health Interview and Examination Survey
1998 (GNHIES98) was carried out by the Robert Koch Institute
from October 1997 to March 1999. It was the first nationwide
representative survey on the health status of Germany's adult
population after the German reunification (Bellach et al., 1998).
Participants were recruited using a two-stage stratified cluster
sampling design (for a detailed description of the study design,
see (Bellach et al., 1998; Scheidt-Nave et al., 2012)). In brief, the
first stage selection comprised 120 cities and municipalities,
representative regarding size, location and structure (urbaniza-
tion, regional population density, and administrative borders) for
all German communities. In the second stage a representative
sample of the residential population aged 18–79 years was drawn
from local population registers of the selected communities. In
total 7,124 participants (response rate 61.4%) were interviewed,
medically examined, and blood and urine samples were collected.
Serum samples were stored at 20 C. The study was conducted
according to the Federal and State Commissioners for Data
Protection guidelines and was approved by the Federal Commis-
sioner for Data Protection. Informed consent was obtained from
all participants.Multiplex serology
In 2016/2017, the stored serum samples were tested for
antibodies to the major capsid (L1) protein of 19 different HPV
genotypes at the German Cancer Research Center (DKFZ) in
Heidelberg. HPV types were selected for analysis based on the
following criteria: public health relevance, carcinogenic potential,
disease outcome, and genus- and species-specific broad distribu-
tion (for cutaneous types) (Supplementary Figure 1). The test panel
included twelve mucosal (alpha: 6, 11, 16, 18, 31, 33, 35, 39, 45, 52,
58, 59) and seven cutaneous (alpha: 10; beta: 8, 38, 49; gamma: 4;
nu: 41; mu: 1) HPV genotypes. Serological testing was done by a
glutathione S-transferase (GST) capture immunoassay in combi-
nation with fluorescent bead technology as previously described
(Waterboer et al., 2005). Type-specific HPV seroreactivity was
measured in median fluorescence intensity (MFI) units and
seropositivity was calculated based on previously established
cut-off- values (Clifford et al., 2007). In addition, antibodies against
the following other sexually transmitted infections (STI) were
determined using the same assay: Mycoplasma genitalium (Mg),
Herpes simplex virus 2 (HSV2) and Chlamydia trachomatis (Ct).
Statistical analysis
Seroprevalence was calculated for all 19 types separately and
for the following groups of HPV types: HR types (HPV-HR: 16, 18,
31, 33, 35, 39, 45, 52, 58, 59), LR types: (HPV-LR: 6, 11), mucosal
types (HPV-muc: 6, 11, 16, 18, 31, 33, 35, 39, 45, 52, 58, 59),
cutaneous types (HPV-cut: 1, 4, 8, 10, 38, 41, 49), types included in
the bivalent vaccine (HPV-2val: 16, 18), types included in the
quadrivalent vaccine (HPV-4val: 6, 11, 16, 18), and types included in
the nonavalent vaccine (HPV-9val: 6, 11, 16, 18, 31, 33, 45, 52, 58)
(Supplementary Figure 1). Seroprevalence was calculated as the
weighted proportion of participants seropositive to at least one of
the HPV types included in one group. Differences regarding
demographic and behavioral characteristic of participants strati-
fied by sex were evaluated. All estimates were calculated by
applying a survey weight, adopting the study sample to the
population structure of Germany in 1997 in terms of age, sex, state,
size of municipality, education, German/non-German nationality,
and the regional distribution between East and West Germany
(Thefeld et al., 1999). Age was categorized into 10-year groups (30–
39, 40–49, 50–59, 60–69, 70–79), except for younger participants,
which were categorized into the age groups 18–24 and 25–29 to be
able to identify differences due to sexual behavior. Region of
residence was split into two variables. Region of residence I, West
and East Germany, takes into account the former boarders of the
German Democratic Republic and the Federal Republic of Germany
from 1949 to 1990. Region of Residence II describes the different
states in Germany and is categorized into northern (Berlin,
Brandenburg, Bremen, Hamburg, Lower Saxony, Mecklenburg-
West Pomerania, Schleswig-Holstein), central (Hesse, North
Rhine-Westphalia, Saxony, Saxony-Anhalt, Thuringia) and south-
ern Germany (Baden-Württemberg, Bavaria, Rhineland-Palatinate,
Saarland). Urbanity was categorized as rural (<5000 residents),
small city (5000–<20,000 residents), medium-sized city (20,000–
<100,000 residents) and large city (100,000 residents). Education
refers to the highest academic qualification achieved and is
categorized into low, middle and high based on the International
Standard Classification of Education (ISCED) (1997). Seropositivity
for any other sexually transmitted infection (STI+) was categorized
as the status of being seropositive for at least one of the three
tested STI. We categorized the lifetime number of sexual partners
(LNSP) into the following groups: 0, 1, 2–4, 5–9, and 10 partners.
Chi2-Tests were used to test for statistical significance in
categorical variables (p < 0.05) and logit transformation was
Table 1
Demographic Characteristics of the Study Participants by Sex, HPV Seroprevalence
Study (n = 6517), 2016/2017 (sera collected 1997–1999).
Females Males
Subjects, No. %a Subjects, No. %a
Overall 3,356 50.6 3,161 49.4
Age group (y)
18–24 305 9.4 342 10.0
25–29 274 9.2 237 9.2
30–39 729 21.4 709 24.2
40–49 635 17.8 588 19.1
50–59 636 16.5 624 17.1
60–69 492 14.7 448 13.5
70–79 285 11.0 213 6.8
Region of Residence I
East 1,165 20.9 1,060 20.9
West 2,191 79.1 2,101 79.1
Region of Residence II
Northern Germany 872 25.8 794 26.4
Central Germany 1,535 41.1 1,454 40.7
Southern Germany 949 33.1 913 33.0
Country of Birth
Germany 2,943 83.8 2,797 84.1
Other 315 13.5 286 13.2
NA 98 2.7 78 2.7
Urbanity
Rural 787 20.1 758 20.3
Small City 694 18.8 694 20.6
Medium-sized City 863 28.5 784 27.0
Large City 1,012 32.6 925 32.1
History of Smoking
No 1,823 54.6 1,070 33.4
Yes 1,443 42.8 2,029 64.4
NA 90 2.6 62 2.3
Education
Low 736 29.6 378 16.7
Middle 1,960 53.4 1,695 54.0
High 562 14.2 1,011 26.5
NA 98 2.7 77 2.8
Seropositive for any other STI
No 1,462 44.2 1,344 42.3
Yes 1,894 55.8 1,817 57.7
Lifetime sex partners
0 29 1.1 30 0.9
1 702 20.9 442 13.6
2–4 838 24.0 604 18.4
5–9 311 9.3 402 12.4
10 136 3.9 387 12.8
NA 1,340 40.9 1,296 41.8
History of Use of Contraceptives
No 2,637 79.8 – –
Yes 704 19.8 – –
NA 15 0.5 – –
NA, not available.
a Weighted percentage STI, sexually transmitted infection (i.e. Mycoplasma
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analysis was applied to identify associations of various demo-
graphic and behavioral characteristics with type-specific and HPV
group seropositivity. Multivariable weighted binomial regression
models were developed estimating adjusted prevalence ratios and
their 95% CI for females and males separately. All factors with a p-
value <0.05 in univariable analysis were included in the
multivariable regression model. Data management and statistical
analysis were conducted using Stata, Version 14 (STATA Corp.,
College Station, TX, US).
Results
Serum samples of 6517 participants were successfully tested for
HPV antibodies and included in this study (Figure 1). Included
participants were not different to the full GNHIES98 sample
regarding all baseline socio-demographic characteristics (Supple-
mentary Table 1). Demographic characteristics of the participants
are shown in Table 1.
Mucosal HPV types
Sex- and age-specific seroprevalences of the twelve mucosal
HPV types are presented in Table 2. Seroprevalence ranged from
1.3% (HPV-33) to 12.0% (HPV-6). Overall seroprevalence of HPV
types 6, 11, 16 and 18 were 12.8%, 4.8%, 8.7% and 6.9% among
females, and 11.2%, 3.3%, 4.7% and 5.5% among males, respectively
(Table 2). Analyzing all age groups together, we found slightly
higher HPV seroprevalences of individual mucosal HPV types in
females compared to males in all types except HPV-35.
Seroprevalences of the various HPV types differed by age group,
showing heterogeneous age patterns. Among females, the lowest
seroprevalences of mucosal HPV types were observed in the
youngest age groups, except for HPV-6 and HPV-35, where lowest
seroprevalences were found in the oldest age groups (Table 2).
Compared to younger age groups, seroprevalences slightly
increased in the 30–39 or 40–49-year-olds and remained relatively
stable thereafter. Among females, HPV-16 seroprevalence in-
creased from 5.0% in 18–24-year-olds to a first peak in 30–39-year-
olds (9.6%) and had a second peak in the age group 60–69 years
(10.7%; Table 2). The same pattern was also observed in HPV-6,
HPV-11 and HPV-18 but with the first peak in 40–49-year-olds.
Among males, the highest seroprevalence was found in the age
group 30–59 years. For some HPV types (6, 11, 31, 45, and 52) we
found a decrease in seroprevalence between 18–24-year-old and
25–29-year-old males. HPV-16 slightly increased from 2.7% in 18–
24-year-olds to 4.5% in 25–29-year-olds and thereafter remainedFigure 1. Flow chart of study participants of the HPV seroprevalence study, 2016/
2017. Sera were collected throughout the German National Health Interview and
Examination Survey (GNHIES98).1997–1999.
genitalium, Herpes simplex virus 2, or Chlamydia trachomatis).relatively stable with the highest prevalence of 5.7% among men
aged 50–59 years.
There were only slight regional differences in type-specific HPV
seroprevalence. HPV-16 seroprevalence was lowest among males
in South Germany (3.4%, 95% CI 2.4%–4.7%) compared to North
(5.2%, 95% CI 4.1%–6.6%) and central Germany (5.3%, 95% CI 4.2%–
6.8%) (p = 0.042). Compared to males living in East Germany (5.9%,
95% CI 4.8%–7.4%), males in West Germany had lower HPV-16
seroprevalence (4.3%, 95% CI 3.6%–5.3%, p = 0.039). We observed no
regional differences in HPV-16 seroprevalence among females
(data not shown).
Cutaneous HPV types
Type-specific cutaneous HPV seroprevalence ranged from 8.7%
(HPV-41) to 34.7% (HPV-4). The most prevalent cutaneous HPV
types were 1, 4, and 8 with 34.5%, 33.9%, 18.3% among females, and
Table 2
Seroprevalence of Individual Mucosal Human Papillomavirus Types by Sex and Age, HPV Seroprevalence Study (n= 6517), 2016/2017 (sera collected 1997–1999).
Group Subjects, no. Seroprevalence by HPV type, % (95% CI)
6# 11# 16# 18 31 33 45 52 58 35 39 59

















































18–24 305 8.5 (5.4–13.3) 2.2 (1.1–4.7) 5.0 (3.0–8.2) 4.8 (2.7–8.4) 3.3 (1.8–6.1) 0.5 (0.1–2.2) 1.0 (0.3–2.9) 0.7 (0.1–3.2) 0.9 (0.2–3.3) 4.0 (2.0–7.9) 6.1 (3.5–10.5) 6.5 (4.0–10.3)
28 8 15 13 10 2 4 2 3 13 17 19
25–29 274 14.3 (10.0–20.0) 4.5 (2.1–9.7) 7.4 (4.4–12.4) 6.2 (3.7–10.2) 2.3 (1.1–4.8) 0.2 (0.0–1.7) 1.0 (0.4–2.8) 0.8 (0.2–3.3) 3.6 (1.7–7.4) 5.3 (3.0–9.0) 5.5 (2.9–10.3) 8.0 (5.2–12.0)
37 11 19 17 7 1 4 2 10 15 11 22
30–39 729 14.6 (11.9–17.9) 5.0 (3.5–7.0) 9.6 (7.5–12.2) 6.9 (5.0–9.5) 4.7 (3.2–6.9) 0.6 (0.2–1.4) 3.2 (2.2–4.8) 1.7 (0.9–3.2) 6.8 (4.9–9.2) 6.9 (5.0–9.5) 7.7 (5.7–10.2) 9.8 (7.7–12.5)
111 37 75 51 32 5 25 10 47 46 66 82
40–49 635 16.1 (13.3–19.3) 5.5 (3.8–7.9) 8.2 (6.2–10.7) 8.1 (6.0–10.7) 3.6 (2.2–5.7) 1.8 (0.9–3.4) 3.6 (2.2–5.8) 2.0 (1.1–3.4) 5.6 (4.1–7.6) 5.2 (3.6–7.4) 10.5 (8.1–13.5) 10.8 (8.1–14.2)
102 34 55 51 22 12 22 13 40 36 68 70
50–59 636 10.5 (8.0–13.7) 4.2 (2.8–6.5) 9.3 (7.1–12.0) 5.9 (4.0–8.5) 2.9 (1.7–4.9) 2.4 (1.3–4.6) 2.0 (1.0–4.1) 2.5 (1.3–5.0) 2.7 (1.5–4.9) 5.0 (3.2–7.8) 10.4 (8.0–13.4) 10.0 (7.7–13.1)
67 28 57 36 20 13 12 12 15 28 64 66
60–69 492 14.5 (11.2–18.7) 5.7 (3.6–8.7) 10.7 (7.4–15.2) 8.2 (5.8–11.5) 3.6 (2.2–5.8) 1.6 (0.8–3.3) 4.4 (2.6–7.2) 3.6 (2.0–6.4) 4.3 (2.5–7.5) 3.8 (2.4–6.1) 10.8 (8.1–14.3) 14.2 (11.1–17.9)
67 27 54 40 19 9 20 15 19 20 57 66
70–79 285 7.6 (5.1–11.3) 5.6 (2.9–10.6) 8.1 (5.1–12.7) 6.9 (4.3–11.0) 3.3 (1.3–8.0) 1.5 (0.6–4.0) 4.5 (2.6–7.8) 4.1 (2.0–8.4) 2.3 (0.8–6.6) 5.6 (3.1–10.0) 7.7 (4.5–12.6) 10.4 (7.0–15.1)
27 16 24 20 9 5 14 13 9 18 23 30

























18–24 342 12.5 (8.8–17.4) 3.5 (1.8–6.7) 2.7 (1.4–5.2) 4.9 (3.0–7.9) 2.6 (1.4–4.9) 0.5 (0.1–2.1) 2.2 (1.1–4.4) 1.7 (0.8–3.7) 3.3 (1.7–6.4) 5.6 (3.6–8.7) 5.2 (3.2–8.5) 6.1 (3.9–9.3)
42 11 9 18 9 2 8 7 11 19 20 25
25–29 237 9.0 (5.6–14.1) 0.8 (0.2–3.6) 4.5 (2.3–8.5) 5.5 (3.3–9.2) 1.5 (0.6–3.8) 0.5 (0.1–3.6) 1.7 (0.7–4.5) 1.0 (0.3–3.3) 3.3 (1.5–7.0) 7.7 (4.6–12.6) 6.1 (3.5–10.4) 10.9 (6.6–17.4)
22 2 13 14 5 1 5 3 8 18 14 26
30–39 709 14.3 (11.5–17.6) 5.0 (3.4–7.2) 4.7 (3.3–6.7) 5.5 (3.6–8.5) 3.7 (2.2–6.3) 1.9 (0.9–3.9) 2.9 (1.6–5.3) 2.3 (1.2–4.3) 6.2 (4.4–8.7) 7.2 (5.2–9.9) 7.9 (5.9–10.6) 7.2 (5.3–9.6)
96 30 35 33 20 11 17 12 43 50 53 48
40–49 588 15.5 (12.3–19.2) 3.8 (2.2–6.4) 5.4 (3.5–8.1) 5.0 (3.0–8.3) 3.1 (1.9–4.8) 1.5 (0.8–2.8) 1.8 (0.8–4.0) 2.1 (1.0–4.2) 5.7 (3.6–8.7) 7.2 (5.1–9.9) 7.2 (5.1–10.0) 7.4 (5.3–10.2)
83 18 30 24 18 10 8 10 34 40 38 42
50–59 624 7.4 (5.6–9.8) 2.3 (1.3–4.0) 5.7 (4.2–7.7) 6.4 (4.6–8.8) 2.6 (1.6–4.2) 0.8 (0.4–2.0) 1.8 (1.0–3.2) 1.5 (0.8–2.7) 2.6 (1.5–4.5) 5.2 (3.6–7.4) 9.3 (6.9–12.5) 11.1 (8.4–14.4)
49 12 37 39 18 6 12 11 15 33 52 63
60–69 448 7.4 (5.2–10.5) 2.8 (1.6–4.8) 4.0 (2.6–6.2) 5.4 (3.4–8.3) 2.1 (1.1–3.8) 0.5 (0.1–2.0) 2.8 (1.4–5.5) 1.1 (0.5–2.4) 0.5 (0.2–1.4) 4.6 (2.9–7.2) 9.0 (6.6–12.1) 11.6 (8.7–15.2)
40 14 22 25 10 2 10 7 4 25 40 48
70–79 213 5.7 (3.1–10.3) 2.2 (0.9–5.6) 4.3 (2.2–8.2) 5.7 (3.1–10.3) 2.6 (1.1–6.5) 1.1 (0.3–3.6) 1.3 (0.5–3.6) 1.1 (0.4–3.2) 1.3 (0.5–3.7) 6.7 (3.8–11.4) 9.0 (5.6–14.2) 11.3 (7.6–16.4)
11 5 10 14 5 3 4 4 4 15 20 22
Note. CI, confidence interval.
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cutaneous HPV seroprevalence are provided in Supplementary
Table 2. Compared to mucosal types, we did not find any significant
type-specific differences between both sexes. For some cutaneous
HPV types, i.e., 8, 10, 38 and 49, we observed a general increase in
HPV seroprevalence with age. The age pattern of HPV-1 clearly
differed with a steady decrease from 46.4% to 21.3% among females
and 39.8% to 26.6% among males.
Grouped HPV types
Seropositivity against at least one mucosal HPV type (HPV-muc,
35.3%) or any HPV-HR type (HPV-HR, 27.9%) showed slight but
statistically significant higher seroprevalences in females as
compared to male participants (Table 3). This constellation was
also observed in other subgroups (HPV-2val, HPV-4val, HPV-9val,
HPV-LR), reflecting mainly the sex-specific seroprevalence differ-
ences in HPV-6, HPV-11 and HPV-16. Age-specific seroprevalences
for HPV types included in the vaccines and for those assigned to the
HR and LR group are shown in Figure 2 and Figure 3.
Multiple seropositivity
While 18.4% were positive for only one HPV-HR type, 4.9% were
positive for two and 4.6% for 3 different HPV-HR types
(Supplementary Table 3). There was no significant difference in
this distribution between females and males.
Risk factors
The risk factor analysis was restricted to HPV types included in
the 4-valent vaccine and the HR and LR type groups. The results
related to HPV-16 are shown in Table 4; the remaining results are
shown in the supplement (Supplementary Table 4–Supplementary
Table 8). In univariable analysis, STI+, LNSP, age and urbanity wereFigure 2. Seropositivity of grouped Human Papillomavirus (HPV) types in 3356 females 
1 of 6 or 11; HPV-4val: 1 of 6, 11, 16 or 18; HPV-9val: 1 of 6, 11, 16, 18, 31, 33, 45,
Table 3
Seroprevalence of grouped Human Papillomavirus (HPV) Types by Sex, HPV Seropreva
HPV types, grouped Overall 
1 of 2-valent vaccine (HPV-2val) 10.7 (9.9–11.6) 
1 of 4-valent vaccine (HPV-4val) 20.6 (19.5–21.8) 
1 of 9-valent vaccine (HPV-9val) 24.9 (23.7–26.1) 
1 of mucosal (HPV-muc) 35.3 (33.7–36.8) 
1 of cutaneous (HPV-cut) 63.6 (61.9–65.2) 
1 of High Risk (HPV-HR) 27.9 (26.4–29.4) 
1 of Low Risk (HPV-LR) 13.3 (12.3–14.4) 
* Females vs males.significantly associated with HPV-16 seropositivity among females
(Table 4), and were therefore included in our final multivariable
model. In the model, all variables remained significantly associated
with HPV-16 seropositivity except age. Females living in medium-
sized cities were more likely to be seropositive than females living
in rural areas, small or large cities. STI+ females as well as females
with higher LNSP were more likely to be HPV-16 seropositive.
Among males, STI+, LNSP, age and region of residence were
significantly associated with HPV-16 seropositivity in the uni-
variable analysis. In the multivariable analysis, STI+ was associated
with higher HPV-16 seropositivity, while living in the southern
part of Germany was associated with lower HPV-16 seropositivity.
Discussion
We assessed the prevalence of antibodies against 19 different
mucosal and cutaneous HPV types in the adult population in
Germany before the introduction of routine female HPV vaccina-
tion. Therefore, these data provide an estimate of naturally
acquired and cumulative type-specific HPV exposure (Robbins
et al., 2014). Being positive for any HPV type included in the
recently licensed 9-valent HPV vaccine was common with 26.9%
among females and 22.8% among males. Being seropositive for any
other tested STI and having a higher lifetime number of sexual
partners were the strongest factors associated with HPV-16
seropositivity.
Most previous studies on HPV infections in Germany were
based on HPV DNA in genital samples collected from young women
(Delere et al., 2014; Iftner et al., 2010; Petry et al., 2013). Using this
approach, one study showed that HPV-16 was the predominant
vaccine-relevant HPV-HR genotype in Germany with 19.5% among
20–22-year-old females (Delere et al., 2014). This was also
observed in other HPV DNA studies in Germany and is in
accordance with data collected worldwide (Bruni et al., 2010; de
Sanjose et al., 2007; Iftner et al., 2010; Petry et al., 2013). Comparedliving in Germany by age (HPV-LR: 1 of 6 or 11; HPV-HR: 1 of 16 or 18; HPV-2val:
 52 or 58). HPV seroprevalence study 2016/2017 (sera collected 1997–1999).
lence Study (n = 6517), 2016/2017 (sera collected 1997–1999).
Seroprevalence, % (95% CI)
Female Male p-Value*
12.7 (11.4–14.1) 8.7 (7.5–9.9) <0.01
22.9 (21.3–24.6) 18.3 (16.9–19.8) <0.01
26.9 (25.1–28.8) 22.8 (21.4–24.3) <0.01
36.9 (34.8–39.0) 33.6 (31.7–35.6) <0.05
62.5 (60.6–64.4) 64.7 (62.2–67.0) 0.14
29.3 (27.3–31.4) 26.4 (24.5–28.3) <0.05
14.6 (13.2–16.0) 12.0 (10.8–13.4) <0.01
Figure 3. Seropositivity of grouped Human Papillomavirus (HPV) types in 3161 males by age (HPV-LR: 1 of 6 or 11; HPV-HR: 1 of 16 or 18; HPV-2val: 1 of 6 or 11; HPV-
4val: 1 of 6, 11, 16 or 18; HPV-9val: 1 of 6, 11, 16, 18, 31, 33, 45, 52 or 58). HPV seroprevalence study 2016/2017 (sera collected 1997–1999).
Table 4
Factors Associated with Seropositivity to Human Papillomavirus Type 16 Stratified by Sex, HPV Seroprevalence Study, 2016/2017 (sera collected 1997–1999).
Variable Females Males
Crude PR (95% CI) Fully aPR (95% CI) $ Crude PR (95% CI) Fully aPR (95% CI) $
Age groups (y)
18–24 Reference Reference Reference Reference
25–29 1.49 (0.69–3.18) 1.17 (0.54–2.53) 1.68 (0.64–4.40) 1.61 (0.61–4.22)
30–39 1.91 (1.09–3.35) 1.45 (0.83–2.55) 1.76 (0.81–3.84) 1.51 (0.67–3.42)
40–49 1.63 (0.93–2.87) 1.21 (0.69–2.10) 2.00 (0.86–4.62) 1.67 (0.71–3.93)
50–59 1.85 (1.06–3.23) 1.45 (0.84–2.50) 2.12 (1.03–4.38) 1.90 (0.90–4.00)
60–69 2.13 (1.16–3.93) 1.61 (0.90–2.89) 1.51 (0.69–3.29) 1.32 (0.59–2.94)
70–79 1.62 (0.85–3.08) 1.16 (0.61–2.20) 1.61 (0.61–4.27) 1.43 (0.53–3.88)
Region of residence I
East Germany Reference na* Reference Reference
West Germany 0.81 (0.65–1.02) na* 0.73 (0.55–0.98) 0.89 (0.65–1.22)
Region of residence II
Northern Germany Reference na* Reference Reference
Central Germany 1.17 (0.86–1.60) na* 1.02 (0.73–1.43) 1.04 (0.75–1.44)
Southern Germany 1.03 (0.71–1.48) na* 0.64 (0.43–0.97) 0.69 (0.45–1.07)
Country of birth
Germany Reference na* Reference na*
Other 1.01 (0.63–1.62) na* 0.88 (0.43–1.80) na*
Urbanity
Rural Reference Reference Reference na*
Small city 0.94 (0.63–1.40) 0.95 (0.64–1.39) 1.25 (0.75–2.06) na*
Medium-sized city 1.44 (1.02–2.02) 1.48 (1.07–2.04) 1.47 (0.94–2.30) na*
Large city 1.06 (0.74–1.51) 1.01 (0.72–1.43) 1.26 (0.83–1.91) na*
History of smoking
No Reference na* Reference na*
Yes 1.12 (0.86–1.46) na* 0.73 (0.51–1.06) na*
Education
Low 1.24 (0.90–1.72) na* 0.81 (0.41–1.59) na*
Middle Reference na* Reference na*
High 0.95 (0.68–1.32) na* 1.12 (0.81–1.55) na*
Seropositive for any other STI
No Reference Reference Reference Reference
Yes 2.48 (1.84–3.34) 2.29 (1.67–3.12) 2.73 (1.72–4.35) 2.51 (1.56–4.04)
Lifetime no. of sex partners
0 no+ no+ 2.65 (0.53–13.16) 3.08 (0.63–15.09)
1 Reference Reference Reference Reference
2–4 1.31 (0.91–1.88) 1.23 (0.85–1.79) 1.46 (0.66–3.20) 1.36 (0.63–2.93)
5–9 2.17 (1.33–3.52) 1.83 (1.10–3.04) 1.70 (0.76–3.81) 1.55 (0.70–3.41)
> = 10 2.40 (1.39–4.13) 1.97 (1.07–3.63) 2.46 (1.24–4.87) 2.00 (1.02–3.93)
NA 1.85 (1.25–2.74) 1.63 (1.13–2.36) 2.09 (1.18–3.71) 1.88 (1.07–3.29)
History of use of oral contraceptives
No Reference na* – –
Yes 1.02 (0.77–1.35) na* – –
Abbreviations: aPR, adjusted prevalence ratio; CI, confidence interval; na, not available; STI, sexually transmitted infection.
na* variables were not significantly associated with HPV seroprevalence in the univariable model and therefore not included in the fully adjusted model.
no+ no observations in categories.
$ the aPR are adjusted for all variables which are listed in the table and remained in the final model.
Statistically significant PR are shown in bold font.
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prevalent in our study, which is in agreement with previous HPV
seroprevalence studies (Liu et al., 2016; Scherpenisse et al., 2012),
even though comparing serological results based on different
assays remains difficult. Apart from methodological differences,
heterogeneity in HPV-16 seroprevalence among populations in
different countries and regions has to be taken into account
(Vaccarella et al., 2010). In general, HPV-16 seroprevalence was
lower in our study compared to other population-based seroprev-
alence studies (Liu et al., 2016; Markowitz et al., 2009; Newall et al.,
2008; Wang et al., 2003). However, in a seroprevalence study with
sera from 34–82-year-old adults in Germany collected in the late
1980s, HPV-16 seroprevalence among females was only slightly
higher than in our study (10.4%), and nearly the same for males
(4.3%) (Michael et al., 2008). Regarding the four vaccine-relevant
HPV types 6, 11, 16 and 18, we observed similar results with the
highest seroprevalence in HPV-6 as reported in other population-
based HPV seroprevalence studies (Introcaso et al., 2014; Liu et al.,
2016; Markowitz et al., 2009; Newall et al., 2008).
The overall lower seroprevalence in mucosal HPV types among
males compared to females is consistent with other studies
(Markowitz et al., 2009; Michael et al., 2008; Newall et al., 2008;
Scherpenisse et al., 2012), even though the quantitative difference
of HPV seroprevalence between men and women varies. While
population studies in the US (Markowitz et al., 2009) and England
(Desai et al., 2011) showed a greater difference (depending on the
HPV types) in seroprevalence between women and men, the
observed differences were less strong in our results as also
observed in other population surveys in the Netherlands (Scher-
penisse et al., 2012) or Australia (Newall et al., 2008). The overall
sex difference has not been observed in studies using HPV DNA
assays, where men had similar HPV infection rates and a relative
stable risk for acquiring new HPV infections over age (Dunne et al.,
2006; Giuliano et al., 2011). The difference in mucosal HPV
seroprevalence might be a result of a different (keratinized)
epithelium at the infection site, but has also been attributed to a
shorter average duration of infection in men, leading to a reduced
chance of developing HPV antibodies (Carter et al., 2000;
Markowitz et al., 2009). Our present findings showed that HPV-
4val seropositivity peaked later among men (40–49-year-olds)
than among women, which was comparable to seroprevalence
data from Australia (32% at 40–49-year-olds) and the US (18% at
50–59-year-olds) (Markowitz et al., 2009; Newall et al., 2008).
Population-wide surveys offer the opportunity to draw con-
clusions on trends over age groups. We observed a slight increase
in HPV-HR seroprevalence mainly among females in the youngest
age groups, from 18 to 24 years to 30–39 years, which is consistent
with other seroprevalence studies (Liu et al., 2016), probably
reflecting the onset of sexual activity and the increasing number of
sex partners in those age groups. HPV-4val among females was
generally lower and reached a later age peak with 26.7% in 40–49-
year-olds compared to peak seropositivity at 30–39-year-olds in
Australia (39%) and the US (42%) (Markowitz et al., 2009; Newall
et al., 2008). We also observed a lower HPV-9val seropositivity in
females in our study as compared to a study from the US (40.5%),
while HPV-9val prevalence in males was comparable between
these two studies (Markowitz et al., 2009).
In contrast to other studies, we did not observe in older age
groups a lower seroprevalence in vaccine-relevant HPV types,
except for HPV6 and HPV58 in males. This lower seroprevalence in
older age groups was explained by other authors as a result of
cohort effects or waning antibodies, even though the humoral
response is considered to be relatively stable over time (Newall
et al., 2008; Ryser et al., 2017; Tiggelaar et al., 2012; Wang et al.,
2003). In general, HPV prevalences in men are described to be less
influenced by age compared to women (Giuliano et al., 2011).However, in our study a relatively stable age-related seropreva-
lence trend was observed in both sexes.
Previous studies described a second peak in HPV DNA
prevalence among older women in some but not all geographic
regions (Castle et al., 2005; de Sanjose et al., 2007; Gravitt et al.,
2013; Trottier et al., 2010). However, this second peak was not
observed in most population-based seroprevalence studies (Liu
et al., 2016; Markowitz et al., 2009; Newall et al., 2008). Despite a
relatively stable seroprevalence over age in our present findings,
we observed a second age peak in HPV seroprevalence for some
HPV types (6, 11, 16, 39, 58, and 59) among 60–69-year-old women.
The second age peak in older women is discussed as a menopause-
related hormonal change which possibly reactivates latent HPV
infections (Althoff et al., 2009; Castle et al., 2005; de Sanjose et al.,
2007; Gravitt et al., 2013; Gravitt and Winer, 2017). Another
hypothesis is that the peak might reflect new HPV infections
because of sexual behavior change in women of older ages and
their partners (Trottier et al., 2010). However, it is also discussed
that seroprevalence differences in older women are a cohort effect
(de Sanjose et al., 2007; Ryser et al., 2017; Trottier and Franco,
2006).
As compared to individual mucosal HPV seroprevalence among
older age groups, our data showed that HPV seroprevalence in the
youngest age groups was relatively high. The HPV-HR seropreva-
lence of nearly 10% in 18–24-year-old participants underlines the
importance of vaccination at a young age before sexual debut.
However, the observed second peak of individual mucosal HPV
seroprevalence indicates that in older women reactivation of prior
infections as well as incident HPV infections should be considered.
Type- and age-specific seroprevalence of cutaneous HPV types
was comparable with other studies with an age-related increase in
cutaneous HPV types except for HPV-1 (Antonsson, 2012; Rahman
et al., 2016b). Since HPV-1- and HPV-4-related warts are common
among children and adolescents the high prevalence of HPV-1 and
HPV-4 among the youngest participants of our study is not an
unexpected finding (Antonsson, 2012).
Behavioral factors associated with seropositivity in our study
were similar to those reported elsewhere (Liu et al., 2016;
Markowitz et al., 2009). Age was associated with HPV-16
seropositivity in both sexes only in univariable analysis. In the
final model, independent predictors of HPV-16 seropositivity were
the presence of antibodies to other STI and LNSP, which was similar
to those reported elsewhere (Liu et al., 2016; Scherpenisse et al.,
2012; Vaccarella et al., 2010; Wang et al., 2003). Given that being
STI+ was the strongest associated factor in nearly all HPV types, STI
+ could be a useful marker of sexual behavior, in addition to the
potentially biased self-reported LNSP. In contrast to previous
studies (Liu et al., 2016; Rahman et al., 2016a; Vaccarella et al.,
2010), we did not observe any association between age and HPV-16
and HPV-18 seropositivity, which could be explained by different
age categorizations.
Several studies have supported HPV antibody seropositivity as a
biomarker of past HPV exposure (Hariri et al., 2008; Liu et al., 2016;
Markowitz et al., 2009; Newall et al., 2008; Wang et al., 2003). In
our study, seropositivity was measured by a GST fusion protein-
based multiplex serological assay that has been used in several
other HPV seroprevalence studies (Clifford et al., 2007; Michael
et al., 2008; Rahman et al., 2016a; Rahman et al., 2016b; Wilson
et al., 2014). However, our prevalence data may not be directly
comparable with studies using different antigen preparations (e.g.
virus-like particles) and other cut-off definitions in their assays.
Besides these technique-based differences, seroprevalence differ-
ences between countries may also be explained by underlying
populations, sampling time, and differences in exposures related to
HPV transmission like sexual behaviors. Seropositivity is not a
perfect HPV exposure measure as it tends to underestimate the
10 A.D. Loenenbach et al. / International Journal of Infectious Diseases 83 (2019) 3–11cumulative exposure (Introcaso et al., 2014). This is due to various
factors, i.e., the impact of a broad range of sex-, type- and infection
site-specific seroconversion rates, infection clearance and the still
unknown seropositivity duration (Brouwer et al., 2015; Carter
et al., 2000; Edelstein et al., 2011; Giuliano et al., 2015; Lu et al.,
2012). Furthermore, natural HPV infections result in much lower
immune response and seroconversion rates, compared to HPV
vaccination (Harper et al., 2006). Therefore, the presented
estimates of seroprevalence also might be an underestimation
of cumulative HPV exposure.
Our study has several strengths. It was based on a large,
representative sample of the population of Germany, and a large
demographic and behavioral data set; blood samples were
collected using highly standardized sampling methods. Using
these blood samples from the prevaccine era, we were able to
measure naturally acquired antibodies to 19 mucosal and
cutaneous HPV types in a single laboratory test. In addition, the
antibody prevalence against other common STI was used as a proxy
for sexual activity. Finally, using nationally representative data of
GNIEHS98 it was possible to estimate the type-specific HPV
seroprevalence in demographic groups in Germany and to identify
factors associated with type-specific seropositivity in men and
women.
However, we are also aware of some limitations of our study
which should be considered when interpreting the results. Serum
samples were properly stored at 20 C since the collection in
1997–1999, but storage time could still have an effect on sera
quality and antibody concentration. However, this would affect all
samples and could not explain group-specific differences, like age-,
sex- or type-specific prevalence.
In conclusion, we generated data on type-specific HPV
seroprevalence in the general population of adults living in
Germany, for all age groups and both sexes. These data were
collected before HPV vaccine introduction and will serve as
baseline estimates for naturally derived cumulative type-specific
HPV exposure in Germany in non-vaccinated individuals. HPV
seroprevalence studies in the adult population after vaccine
introduction as well as in children and adolescents are currently
underway in Germany and can be used to assess the population-
level (indirect) effects of HPV vaccination, which has been initially
carried out in Germany mainly with 4-valent and since 2016
mainly with 9-valent HPV vaccines.
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